scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Sold by J. Goldman & Co LP

J. Goldman & Co LP lowered its position in shares of scPharmaceuticals Inc. (NASDAQ:SCPHGet Rating) by 81.8% during the first quarter, Holdings Channel reports. The fund owned 67,500 shares of the company’s stock after selling 302,591 shares during the quarter. J. Goldman & Co LP’s holdings in scPharmaceuticals were worth $383,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of SCPH. Envestnet Asset Management Inc. boosted its position in scPharmaceuticals by 20.4% during the fourth quarter. Envestnet Asset Management Inc. now owns 12,882 shares of the company’s stock worth $65,000 after acquiring an additional 2,186 shares during the last quarter. IPG Investment Advisors LLC acquired a new stake in scPharmaceuticals during the fourth quarter worth approximately $72,000. Belvedere Trading LLC acquired a new stake in scPharmaceuticals during the first quarter worth approximately $822,000. Simplex Trading LLC boosted its position in scPharmaceuticals by 2,366.0% during the first quarter. Simplex Trading LLC now owns 23,156 shares of the company’s stock worth $131,000 after acquiring an additional 22,217 shares during the last quarter. Finally, AIGH Capital Management LLC boosted its position in scPharmaceuticals by 1.7% during the first quarter. AIGH Capital Management LLC now owns 1,396,724 shares of the company’s stock worth $7,933,000 after acquiring an additional 23,600 shares during the last quarter. Institutional investors and hedge funds own 57.28% of the company’s stock.

Insider Activity

In other news, major shareholder 5Am Partners Iv, Llc sold 26,622 shares of the firm’s stock in a transaction on Tuesday, September 6th. The shares were sold at an average price of $5.52, for a total value of $146,953.44. Following the transaction, the insider now owns 120,062 shares of the company’s stock, valued at approximately $662,742.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.70% of the company’s stock.

scPharmaceuticals Trading Down 0.2 %

Shares of SCPH opened at $4.76 on Friday. The company’s fifty day moving average is $5.45 and its two-hundred day moving average is $5.18. scPharmaceuticals Inc. has a fifty-two week low of $3.48 and a fifty-two week high of $7.24. The company has a current ratio of 3.72, a quick ratio of 3.72 and a debt-to-equity ratio of 0.06.

Analyst Ratings Changes

A number of brokerages recently issued reports on SCPH. SVB Leerink raised their target price on shares of scPharmaceuticals to $6.00 and gave the stock a “market perform” rating in a research report on Tuesday, May 17th. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of scPharmaceuticals in a report on Wednesday, July 13th. Finally, Maxim Group began coverage on shares of scPharmaceuticals in a report on Tuesday, August 2nd. They issued a “buy” rating and a $10.00 price target on the stock.

scPharmaceuticals Profile

(Get Rating)

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure.

Featured Articles

Want to see what other hedge funds are holding SCPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for scPharmaceuticals Inc. (NASDAQ:SCPHGet Rating).

Institutional Ownership by Quarter for scPharmaceuticals (NASDAQ:SCPH)

Receive News & Ratings for scPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for scPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.